Maps Laboratories

Lykos Therapeutics, formerly known as MAPS Public Benefit Corporation, is a clinical-stage biotechnology company focused on developing psychedelic-assisted therapies for mental health conditions. The company's lead program involves the use of midomafetamine (MDMA) in conjunction with psychological intervention for the treatment of post-traumatic stress disorder (PTSD). Lykos has completed two pivotal Phase 3 clinical trials demonstrating significant efficacy and safety, leading to a New Drug Application (NDA) submission to the FDA. As a public benefit corporation, the company balances its profit-making goals with a mission to maximize social impact and patient access to innovative mental health treatments.